PHARMACEUTICAL group Elan has announced that its subsidiary, Athena Neurosciences, has reached agreement with US company Pharmavene to license the worldwide rights to the anti-epileptic medication, Carbatrol.
PHARMACEUTICAL group Elan has announced that its subsidiary, Athena Neurosciences, has reached agreement with US company Pharmavene to license the worldwide rights to the anti-epileptic medication, Carbatrol.